Symatese has just concluded an agreement for its range of dermal fillers, based on its First-Generation Cold Technology HA, with Evolus, one of the major players in the American market. According to Jean-Paul Gérardin, CEO of SYMATESE, “this new partnership represents a tremendous growth lever for the organization which will launch its new range of products in various territories based on solid clinical data”. For more details access the press release & presentation